News

EffRx Pharmaceuticals Statement on COVID-19

March 23, 2020

EffRx Pharmaceuticals Statement on COVID-19

The globe has literally gone into quarantine due to the COVID-19 outbreak. This is an unprecedented crisis situation in terms of breadth and scale, from a global health, social and economic standpoint.

While committed to keep our core activities unaffected, EffRx has implemented measures aimed at guaranteeing business operation continuity, with particular focus on the supply of Binosto® to our customers. EffRx has engaged with its suppliers and clients to ensure continuity of the business and will continue to monitor the situation as it evolves with the aim to minimize the impact of this crisis on our business.

EffRx has further taken internal measures to reduce the contamination risk for employees and business partners. The health of our staff and partners is our number one priority. The entire staff is working remotely from home with effective equipment & systems. We have also cancelled all travels, replaced face-to-face meetings/trainings by virtual meetings and are pursuing digital collaboration with all our stakeholders.

We thank for your loyalty, flexibility and understanding for the unforeseen consequences of this global pandemic. We are in this together.

Wishing you all good health.

EffRx Pharmaceuticals
Lorenzo Bosisio
CEO